Minervax ApS Secures $176.61 Million to Advance Life-Saving Maternal Vaccine for Group B Streptococcus Infections

Minervax ApS, a pioneering biotechnology company focused on maternal health, has successfully raised €176.61 million in funding to advance its groundbreaking vaccine development project. The company is at the forefront of combatting Group B Streptococcus (GBS), the leading cause of life-threatening infections in newborns and a significant contributor to adverse pregnancy outcomes such as stillbirths, late abortions, and preterm deliveries. With an impressive and innovative vaccine strategy based on adjuvanted protein antigens that cover nearly 100% of clinical GBS isolates, Minervax aims to provide a vital safeguard for both mothers and their newborns. Each year, GBS leads to approximately 320,000 cases of neonatal invasive disease and tens of thousands of stillbirths globally, translating into a public health crisis that urgently needs resolution. This funding will enable Minervax to accelerate clinical trials and further develop its vaccine, ultimately driving toward regulatory approval and making a transformative impact on maternal and neonatal health outcomes. The investment underscores the growing recognition of the urgent need for GBS prevention strategies, further solidifying Minervax’s role as a leader in maternal vaccines. By equipping pregnant women with the means to prevent GBS colonization, Minervax is taking significant steps to turn the tide against GBS-associated complications, paving the way for healthier pregnancies and safer beginnings for countless newborns around the world.